A Phase 2 interventional study of IMVT-1402 in Graves' Disease, sponsored by Immunovant Sciences GmbH. Enrolling by invitation at 131 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Graves Disease with a site in United States — 16 open to participants now, 18 under way, 3 of them phase 3. Graves Disease · United States.
Among the 43 studies in Graves Disease with a site in United States, this one has the largest planned enrollment of the 33 interventional ones that give a count, is one of 10 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 17 of the 17 other live ones, and was the 35th registered.
162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
Browse Graves Disease studies →16 of the 43 studies in Graves Disease with a site in United States are open now. Recruiting first, the newest first:
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Biogen · Sites in United States, Puerto Rico
Ages 18–75
Appalachian State University · Sites in United States
Ages 18–65
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Biohaven Therapeutics Ltd. · Sites in United States, Canada, Puerto Rico
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 10 · Phase 4 4
First in 1993; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 372 is above the median of 60 across 104 interventional studies indexed under Graves Disease.
Median enrollment 76 across the 33 interventional studies, 42 across the 10 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Immunovant Sciences GmbH has 4 studies filed under Graves Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05435547Indiana UniversityPreoperative Corticosteroids in Autoimmune Thyroid Disease | 2026-12-30 |
| NCT07413874Appalachian State UniversityTelehealth Music Therapy for Adults With Endocrine Disorder and Depression | 2026-12-31 |
| NCT07018323Immunovant Sciences GmbHA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | 2027-05 |
| NCT06980649Biohaven Therapeutics Ltd.Study of BHV-1300 in Graves' Disease | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Graves Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: IMVT-1402
Dose 1 for up to 52 weeks
Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402
Time frame: At Week 52
Percentage of Group A Participants who are euthyroid and off ATD
Time frame: At Week 26
Percentage of Group A Participants who are euthyroid and off ATD
Time frame: Up to Week 52
Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402
Time frame: Up to Week 52
Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants
Time frame: Up to Week 52
Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: Up to Week 52
Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: At Week 52
Time from Week 0 to the earliest date of confirmed relapse in Group B Participants
Time frame: Up to Week 52
Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: Up to Week 52
Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402
Time frame: At Week 52
Time From Week 0 to the earliest date of confirmed relapse in Group C Participants
Time frame: Up to Week 52
Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb
Time frame: At Week 26
Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb
Time frame: Up to Week 52
Showing the first 100 of 131 sites across 11 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2030, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imeroprubart
Immunovant Sciences GmbH